相关实验视频
Updated: Jun 1, 2025

Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
这一切都是从这里下游的:RTK/Raf/MEK/ERK路径,质母细胞瘤中的抵抗机制
Rebeca Yakubov1,2, Ramneet Kaloti1,2, Phooja Persaud1,2
1MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
针对转录因子提供了一种新的策略,以克服质母细胞瘤 (GBM) 治疗中的耐药性. 抑制受体氨酸激酶 (RTK) /Ras/Raf/MEK/ERK通路可以与转录因子疗法相结合,以改善GBM结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症信号通路 癌症信号通路
背景情况:
- 受体氨酸激酶 (RTK) /Ras/Raf/MEK/ERK通路在质母细胞瘤 (GBM) 中经常过度激活,导致瘤的攻击性行为.
- 尽管有针对性的疗法,临床成功受限于这种途径内的获得性耐药机制.
研究的目的:
- 审查RTK/Ras/Raf/MEK/ERK通路的抑制如何影响转录因子.
- 探索转录因子失调对GBM获得性耐药性的贡献.
- 突出转录因子改变在治疗耐药性的作用.
主要方法:
- 对GBM中RTK/Ras/Raf/MEK/ERK通路的关键研究结果的综合.
- 探索针对性疗法,辐射和化疗的转录因子失调的反应.
主要成果:
- 抑制RTK/Ras/Raf/MEK/ERK通路导致显著的转录因子失调.
- 这种失调是导致GBM治疗耐药性的关键机制.
结论:
- 转录因子代表了克服GBM治疗耐药性的有希望的治疗标.
- 涉及RTK/Ras/Raf/MEK/ERK通路抑制剂和转录因子向疗法的组合策略提供了一种新的方法.
- 准确医学的持续研究和进步对于完善这些策略和改善患者的治疗结果至关重要.
更多相关视频
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
PI3K/mTOR/AKT Signaling Pathway
Treatment Resistant Cancers
MAPK Signaling Cascades
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...